Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
Julinda Mehilli, MD*,*,
Adnan Kastrati, MD*,
Robert A. Byrne, MB, MRCPI*,
Olga Bruskina, MD*,
Raisuke Iijima, MD*,
Stefanie Schulz, MD*,
Jürgen Pache, MD*,
Melchior Seyfarth, MD*,
Steffen Maßberg, MD*,
Karl-Ludwig Laugwitz, MD ,
Josef Dirschinger, MD,
Albert Schömig, MD*, for the ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions) Study Investigators
* Deutsches Herzzentrum, Technische Universität, Munich, Germany
Medizinische Klinik I, Klinikum rechts der Isar, Technische Universität, Munich, Germany
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 1-Year Incidence and Relative Risk of the Primary End Point of Death, Myocardial Infarction, and Target Lesion Revascularization in Pre-Specified Subgroups
Relative risks associated with the use of paclitaxel-eluting stents (PES) as compared with sirolimus-eluting stents (SES) are shown with their 95% confidence intervals (CIs).
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 2-Year Adverse Event Rates in the PES and SES Groups
(A) Mortality. (B) Composite of death, myocardial infarction, and target lesion revascularization. RR = relative risk; other abbreviations as in Figure 2.
|
|
|
